Active Organization- |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC69H92N6O17S |
InChIKeyQTSHFYXEXAHVCR-DBYQZFFGSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 18 Sep 2020 | |
Neoplasms | Preclinical | United States | 18 Sep 2020 | |
Neoplasms | Preclinical | United States | 18 Sep 2020 |